Go Pro
→ Trump Takes Emergency Action - Plus Elon Musk's New Venture (From Altimetry) (Ad)tc pixel
NASDAQ:INVA

Innoviva Q1 2025 Earnings Report

Innoviva logo
$21.82 -0.49 (-2.20%)
Closing price 07/6/2026 04:00 PM Eastern
Extended Trading
$21.86 +0.04 (+0.18%)
As of 08:10 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Innoviva EPS Results

Actual EPS
$0.25
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Innoviva Revenue Results

Actual Revenue
$88.63 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Innoviva Announcement Details

Quarter
Q1 2025
Date
5/7/2025
Time
After Market Closes
Conference Call Date
Wednesday, May 7, 2025
Conference Call Time
12:00AM ET

Upcoming Earnings

Innoviva's Q2 2026 earnings is estimated for Wednesday, August 5, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, July 30, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Innoviva's Q1 2025 Press ReleasePress Release
(8-K)
Innoviva's Q1 2025 Quarterly reportQuarterly report
(10-Q)

Innoviva Earnings Headlines

Innoviva, Inc. (NASDAQ:INVA) Given Average Recommendation of "Moderate Buy" by Brokerages
July 2, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30874516
Major Insider Move Rocks Theravance Biopharma Shares
July 1, 2026  |  tipranks.comhttps://www.tipranks.com/news/insider-trading/major-insider-move-rocks-theravance-biopharma-shares-insider-trading-news?utm_source=marketbeat.com&utm_medium=referral
Stranded On The Flood Plains of History
The petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed U.S. Treasury holdings by 45% from peak, and central banks are swapping dollars for gold at the fastest pace since the Cold War. Porter Stansberry believes Trump is channeling more than $3 trillion toward securing the minerals, chips, and infrastructure that make AI possible - and companies at those chokepoints like Vertiv (up 500%), GE Vernova (up 700%), and Arista Networks (up 750%) are already moving. Porter's new briefing names one asset to buy today plus five stocks positioned at the narrowest chokepoints of what he calls the Silicon Dollar.tc pixel
July 7 at 1:00 AM  |  Porter & Company (Ad)
Is Innoviva (INVA) One of the Best Cheap Small Cap Stocks to Buy Now?
July 1, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/is-innoviva-inva-one-of-the-best-cheap-small-cap-stocks-to-buy-now-1792985/
5 Cheap Small Cap Stocks to Buy Now
June 30, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/5-cheap-small-cap-stocks-to-buy-now-1791285/
Zymeworks Targets Long-Term Cash Generation Through Theravance Acquisition
June 29, 2026  |  benzinga.comhttps://www.benzinga.com/m-a/26/06/60155321/zymeworks-targets-long-term-cash-generation-through-theravance-acquisition
See More Innoviva Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Innoviva? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Innoviva and other key companies, straight to your email.

About Innoviva

Innoviva (NASDAQ:INVA), incorporated in Delaware and headquartered in San Francisco, California, is a royalty-focused life sciences company. It acquires, manages and monetizes royalty and license interests in biopharmaceutical products, with a primary emphasis on inhaled respiratory therapies. Innoviva’s portfolio is anchored by royalties on therapies originally developed by its former affiliate, now marketed by GlaxoSmithKline, including several long-acting inhaled products approved for chronic obstructive pulmonary disease (COPD) and asthma.

The company was established through a spin‐out transaction in 2014, separating the royalty assets from a research‐based biopharmaceutical enterprise to create a specialized investment vehicle. Since its formation, Innoviva has supplemented its core royalty stream with additional licensing and collaboration agreements, and has pursued disciplined capital‐allocation activities to maximize dividend payments to shareholders. The firm’s contractual arrangements typically provide for tiered royalties on net sales as well as potential milestone receipts upon regulatory approvals and commercial launches.

Innoviva’s royalty revenues are generated globally through collaboration partners that market, distribute and promote the underlying therapeutics both in the United States and in international territories. The company maintains a lean corporate structure, relying on third‐party manufacturing, regulatory and commercialization expertise. Innoviva is governed by an experienced board of directors and led by management professionals with backgrounds in pharmaceutical licensing, royalty financing and capital markets.

View Innoviva Profile
Earnings Tools